Table 7.

While LOEs were designed separately for each assertion type, many of the resulting LOEs were alike. As a result, only 15 LOEs were defined for the 22 assertion types in the DIKB’s rule-based theory of metabolic drug-drug interactions. This table enumerates the assertion types that share the same LOEs.

LOE ID	Applies to
A	bioavailability maximum-concentration
B	first-pass-effect fraction-absorbed
C	primary-total-clearance-mechanism
D	controls-formation-of substrate-of is-not-substrate-of
E	primary-total-clearance-enzyme
F	primary-metabolic-clearance-enzyme
G	has-metabolite
H	inhibition-constant
I	inhibits
J	does-not-inhibit
K	does-not-permanently-deactivate-catalytic-function permanently-deactivates-catalytic-function in-vitro-probe-substrate-of-enzyme
L	in-vitro-selective-inhibitor-of-enzyme
M	in-viVo-selective-inhibitor-of-enzyme sole-PK-effect-alter-metabolic-clearance
N	pceut-entity-of-concern
O	polymorphic-enzyme